SCHEMBL301559

SCHEMBL301559

Cc1cc(C)c(P(C2CCCCC2)C2CCCCC2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.40
TAS1R1 Q7RTX1 3/20 0.40
TAS1R2 Q8TE23 3/20 0.40
PSMB5 P28074 1/20 0.37
NR1I2 O75469 1/20 0.36
KDM4B O94953 1/20 0.36
CHRM1 P11229 1/20 0.36
TBXA2R P21731 1/20 0.36
ADRA1A P35348 1/20 0.36
DOHH Q9BU89 1/20 0.36
UGT2B17 O75795 2/20 0.35
NPSR1 Q6W5P4 2/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
ROCK2 O75116 1/20 0.32
EBP Q15125 1/20 0.32
DHCR7 Q9UBM7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26556079 0.79 ROCK2 (0.37) TAS1R3TAS1R1TAS1R2PSMB5ROCK2
SCHEMBL19208899 0.79 ROCK2 (0.38) NPSR1GAAMEN1ALDH1A1TSHR
SCHEMBL16694148 0.78 ROCK2 (0.40) TAS1R3TAS1R1TAS1R2PSMB5NR1I2
SCHEMBL29528470 0.76 ROCK2 (0.37) TAS1R3TAS1R1TAS1R2NR1I2KDM4B
SCHEMBL17529736 0.75 TP53 (0.37) GAAMEN1ALDH1A1TSHRKMT2A
SCHEMBL11954829 0.73 HTT (0.38) GAAMEN1ALDH1A1TSHRKMT2A
SCHEMBL21348992 0.73 ROCK2 (0.38) PSMB5NPSR1GAAMEN1ALDH1A1
SCHEMBL27948023 0.72 ROCK2 (0.39) TAS1R3TAS1R1TAS1R2NR1I2KDM4B
SCHEMBL19058034 0.71 ROCK2 (0.34) TAS1R3TAS1R1TAS1R2PSMB5ROCK2
SCHEMBL11761013 0.71 HRH3 (0.39) TAS1R3TAS1R1TAS1R2PSMB5NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019016115-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED ARYL KETONES BASF Agro B.V. (NL) 2019-01-24 WO claimed
CN-111406059-B Europium complexes 东曹株式会社 2023-04-18 CN disclosed
US-10844073-B2 Palladium-mediated ketolization PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-11-24 US disclosed
WO-2020152200-A1 PROCESS FOR PREPARATION OF HETEROARYLKETONES BASF SE (DE) 2020-07-30 WO disclosed
US-10392400-B2 Palladium-mediated ketolization PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-08-27 US disclosed
WO-2019016115-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED ARYL KETONES BASF Agro B.V. (NL) 2019-01-24 WO disclosed
US-20180244865-A1 INCREASED EFFICIENCY DESULFURIZATION REAGENTS ARLANXEO DEUTSCHLAND GMBH (DE) 2018-08-30 US disclosed
EP-3341432-A1 INCREASED EFFICIENCY DESULFURIZATION REAGENTS ARLANXEO Deutschland GmbH (DE) 2018-07-04 EP disclosed
US-20180155361-A1 PALLADIUM-MEDIATED KETOLIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2018-06-07 US disclosed
EP-2853523-B1 Process for producing fluorine-containing biaryl compound DAIKIN IND LTD (JP) 2018-05-30 EP disclosed
US-20130261305-A1 PROCESS OF MAKING GYRASE AND TOPOISOMERASE INHIBITORS SPERO THERAPEUTICS, INC. 2013-10-03 US disclosed
EP-2610248-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND Teijin Pharma Limited (JP) 2013-07-03 EP disclosed
US-8471014-B2 Process of making gyrase and topoisomerase IV inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-25 US disclosed
US-20130158272-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND TEIJIN PHARMA LIMITED (JP) 2013-06-20 US disclosed
WO-2013032035-A1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-03-07 WO disclosed
WO-2013032035-A1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-03-07 WO disclosed
US-20120184742-A1 PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
WO-2012097274-A1 PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS VERTEX PHARMACEUTICALS INCORPORATION (US) 2012-07-19 WO disclosed
EP-2404908-A1 PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST Teijin Pharma Limited (JP) 2012-01-11 EP disclosed
US-20110313169-A1 PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST TEIJIN PHARMA LIMITED (JP) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313169-A1 PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST XDH, PAH, HPRT1 TAS1R3 3433/4885TAS1R1 3431/4885TAS1R2 3642/4885
US-10844073-B2 Palladium-mediated ketolization ERLIN1, ERLIN2, PDK1 TAS1R3 4518/4885TAS1R1 4448/4885TAS1R2 4609/4885
US-20120184742-A1 PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS TOP1, TOP2A, TOP2B TAS1R3 3664/4885TAS1R1 3881/4885TAS1R2 4204/4885
US-20130158272-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND XDH, AOC1, PAH TAS1R3 4399/4885TAS1R1 4308/4885TAS1R2 4593/4885
US-20180155361-A1 PALLADIUM-MEDIATED KETOLIZATION ERLIN1, ERLIN2, PDK1 TAS1R3 4518/4885TAS1R1 4448/4885TAS1R2 4609/4885
US-10392400-B2 Palladium-mediated ketolization ERLIN1, ERLIN2, PDK1 TAS1R3 4518/4885TAS1R1 4448/4885TAS1R2 4609/4885
US-20130261305-A1 PROCESS OF MAKING GYRASE AND TOPOISOMERASE INHIBITORS TOP1, TOP2A, TOP2B TAS1R3 3434/4885TAS1R1 3669/4885TAS1R2 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.